Incretins|Based Therapies and Their Cardiovascular Effects

The Cardiovascular Biology of Glucagon-like Peptide-1 - Cell Press

Initial studies of GLP-1 focused on its role as incretin hormone ... White, W.B. ∙ Baker, W.L.. Cardiovascular effects of incretin-based therapies.

Exposure–Response Analysis of Cardiovascular Outcome Trials ...

Considering the results of cardiovascular outcome trials (CVOTs) with incretin-based medications, significant heterogeneity in cardiovascular effects could be ...

Perspectives of incretin mimetics in cardiovascular diseases

Incretins : Their physiology and application in the treatment of diabetes mellitus. ... Cardiovascular Effects of Incretin-Based. Therapies. Annu Rev Med. 2016;67 ...

Initial management of hyperglycemia in adults with type 2 diabetes ...

(See "Metformin in the treatment of adults with type 2 diabetes mellitus", section on 'Cardiovascular effects'.) Metformin is far less expensive ...

GLP1RAs in Clinical Practice: Therapeutic Advances and Safety ...

Health care professionals should explore the use of glucagon-like peptide-1 receptor agonists (GLP1RAs) for cardiovascular risk reduction ...

Cardiovascular effects of the DPP-4 inhibitors - Sage Journals

There is a growing body of evidence to suggest that GLP-1 – and as an extension of this, GLP-1 based therapy – may have favourable ...

All about incretins and incretin-based therapies for diabetes treatment

... their mode of action, how gut hormones are released and what effects ... effects incretin-based therapies have on #diabetes and #obesity.

Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes

DPP-4 inhibitors showed neutral effects on cardiovascular outcomes, but may increase the incidence of heart failure. Favourable outcomes ...

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 ...

There are several potential explanations for the finding that a median of 2 years of therapy with saxagliptin did not reduce the rate of ...

Potential Role of GLP-1 Based Therapeutics in Coronary Artery ...

This review summarizes the current research on GLP-1-based therapy for coronary artery disease (CAD) by examining its protective effects against inflammation ...

Cardiovascular Effects of Glucagonlike peptide–1 Agonists

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type. 2 diabetes receiving incretin therapies or insulin in a large ...

Cardiovascular Benefits of Native GLP-1 and its Metabolites - Frontiers

Cardiovascular Effects of GLP-1 7-36a. Numerous studies have shown that GLP-1 exerts cardioprotective actions. These include preserving cardiomyocyte and ...

Incretin Therapies: Advanced Insights for Type 2 Diabetes Care

... Your Trial Access: https://bit.ly/468Wx7f. ... Jens Juul Holst at ARDD2022: Overview of incretin based therapies of metabolic disease.

GLP-1 receptor agonist - Wikipedia

Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1DAs or incretin mimetics, are a class of anorectic drugs that reduce ...

The Evolution of Incretins – A Revolution in Diabetes Management?

The expanding world of glucagon-like peptide-1 (GLP-1) receptor antagonism. What do these developments mean for clinical practice?

8 Metformin Alternatives to Consider for Type 2 Diabetes - GoodRx

If you have advanced kidney disease, insulin may be the best alternative. If you take metformin in addition to another oral diabetes medication, there may be a ...

What is Mounjaro and how does it work? - Diabetes UK

This medication works by activating two receptors called GLP-1 and GIP to increase the level of incretins – hormones - in the body. It works by helping your ...

Current Medicines | Medicines | Eli Lilly and Company

Our growing portfolio of medicines includes treatments in the areas of bone muscle joint, cancer, cardiovascular, diabetes, endocrine, immunology, neuroscience ...

Our medicines | Diabetes medications - Novo Nordisk

Overview of our diabetes medications, obesity medication and also medicines within haemophilia, human growth hormone and hormone replacement therapy.

Diabetes mellitus - Gestational, Risk Factors, Prevention | Britannica

A drug called sitagliptin specifically inhibits DPP-4, thereby increasing levels of naturally produced incretins. Side effects associated with these drugs ...